Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Felis Catus

Phase 1Biologic

UUniversity of North Carolina, Chapel Hill

Felis Catus is one of 42 biologic programs targeting Allergic Asthma. It is currently in Phase 1.

1

Indications

2

Total Trials

0

Active Trials

41

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic AsthmaActive, not recruiting

Allergic AsthmaPhase 1

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Allergic Asthma

#DrugCompanyPhaseTrials

Xolair

Xolair

Symbicort

Levocetirizine Dihydrochloride

Soliris

Daliresp

Tezspire

EBGLYSS

C1-Inhibitor

UUniversitaire Ziekenhuizen KU Leuven

Seretide

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Inflammation1 trial

Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model

Withdrawn·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT03031145

Allergic Asthma1 trial

Identification of Allergic Asthmatics Reactive to Felis Catus (Cat Hair) Allergen Inhalation

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT03780387·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Felis Catus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Felis Catus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Felis Catus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of North Carolina, Chapel Hill

Related News